(Total Views: 538)
Posted On: 04/11/2020 6:06:22 AM
Post# of 148899
Rate of new US hepatitis C infections rises threefold in the past decade, new report finds
https://www.cnn.com/2020/04/10/health/hepatit...index.html
Part of the issue was CDC guidelines, 40% don’t know they have it, and they were not testing younger people, so that nice it moves to that population, it spreads faster.
“Among adults ages 20 to 29, rates increased about 300% from 0.7 per 100,000 in 2009 to 3.1 per 100,000 in 2018. Among adults ages 30 to 39, rates increased about 400%, from 0.5 per 100,000 in 2009 to 2.6 per 100,000 in 2018, according to the report.”
Anyway, leronlimab could help as PrEP or just in general I believe, also with hep b.
CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro
https://journals.plos.org/plosone/article?id=...ne.0224523
Supernatant levels of HCV RNA (expressed as fold change) were not reduced in the presence of raltegravir but were reduced 8.55-fold and 12.42-fold with cenicriviroc and maraviroc, respectively.
Genetic Protection against Hepatitis B Virus Conferred by CCR5Δ32: Evidence that CCR5 Contributes to Viral Persistence
https://jvi.asm.org/content/81/2/441
CCR5Δ32 reduced the risk of developing a persistent HBV infection by nearly half (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.33 to 0.83; P = 0.006).
https://www.cnn.com/2020/04/10/health/hepatit...index.html
Part of the issue was CDC guidelines, 40% don’t know they have it, and they were not testing younger people, so that nice it moves to that population, it spreads faster.
“Among adults ages 20 to 29, rates increased about 300% from 0.7 per 100,000 in 2009 to 3.1 per 100,000 in 2018. Among adults ages 30 to 39, rates increased about 400%, from 0.5 per 100,000 in 2009 to 2.6 per 100,000 in 2018, according to the report.”
Anyway, leronlimab could help as PrEP or just in general I believe, also with hep b.
CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro
https://journals.plos.org/plosone/article?id=...ne.0224523
Supernatant levels of HCV RNA (expressed as fold change) were not reduced in the presence of raltegravir but were reduced 8.55-fold and 12.42-fold with cenicriviroc and maraviroc, respectively.
Genetic Protection against Hepatitis B Virus Conferred by CCR5Δ32: Evidence that CCR5 Contributes to Viral Persistence
https://jvi.asm.org/content/81/2/441
CCR5Δ32 reduced the risk of developing a persistent HBV infection by nearly half (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.33 to 0.83; P = 0.006).
(2)
(0)Scroll down for more posts ▼
